以中孔氧化石墨烯奈米粒子結合表面輔助雷射游離/脫附檢測精神活性物質

Abstract

本研究以中孔氧化石墨烯奈米粒子 (mesoporous graphene oxide nanoparticles, MGNs) 作為新型奈米基質，結合表面輔助雷射游離脫附 (surface-assisted laser desorption/ionization, SALDI) 技術檢測精神活性物質，提升表面質譜檢測之再現性及低荷質比區間 (m/z 100-500) 背景干擾問題。類似於中孔洞沸石奈米粒子 (MZNs) 具有高比表面積 (>900 m2/g) 及孔洞 (5-6 nm) 之高孔容 (≈1 mL/g) 具有優異的吸附藥物能力，MGNs表面因具有氧化石墨烯的強吸光性 (200-900 nm) 及近紅外放光 (1000-2500 nm) 特性，具有優異的光熱轉換效率提供精神活性物質游離/脫附之能量。對照兩種有機酸-基質龍膽酸 (2,5-Dihydroxybenzoic acid, DHB) 、α-氰基-4-羥基肉桂酸 (α-cyano-4-hydroxycinnamic acid, α-CHCA) 和商業化氧化石墨烯 (GO) 檢測精神活性物質的質譜結果，MGNs偵測濃度已達到法規濃度 (50 ppb) 等級且具有更低的背景訊號，且對於真實樣品之定量誤差值小於10%。此外，透過結合自動化技術分離尿液與咖啡包檢體，有望達到即時輔助臨床檢測進行毒癮即時檢測及防治。

In this study, mesoporous graphene oxide nanoparticles (MGNs) were used as a new nano-matrix, combined with surface-assisted laser desorption/ionization (SALDI) technology to detect psychoactive substances. Improve the reproducibility of surface mass spectrometry detection and the background interference problem in the low charge-to-mass ratio range (m/z 100-500). Similar to mesoporous zeolite nanoparticles (MZNs), it has a high specific surface area (>900 m2/g) and a high pore volume (≈1 mL/g) of pores (5-6 nm) with excellent ability to adsorb drugs. The surface of MGNs has Graphene oxide has strong light absorption (200-900 nm) and near-infrared light emission (1000-2500 nm) characteristics, and has excellent photothermal conversion efficiency to provide energy for the dissociation/desorption of psychoactive substances. Comparison of two organic acids-matrix gentisic acid (2,5-Dihydroxybenzoic acid, DHB), α-cyano-4-hydroxycinnamic acid (α-cyano-4-hydroxycinnamic acid, α-CHCA) and commercial graphite oxide The mass spectrometry results of GO detection of psychoactive substances, the detection concentration of MGNs has reached the legal concentration (50 ppb) level and has lower background signals, and the quantitative error value for real samples is less than 10%. It is also possible to separate urine and coffee bag samples by combining automation technology, which is expected Achieve real-time auxiliary clinical detection for real-time detection and prevention of drug addiction.